Cargando…
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures
FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prog...
Autores principales: | Wong, Kah Keng, Gascoyne, Duncan M., Soilleux, Elizabeth J., Lyne, Linden, Spearman, Hayley, Roncador, Giovanna, Pedersen, Lars M., Møller, Michael B., Green, Tina M., Banham, Alison H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288160/ https://www.ncbi.nlm.nih.gov/pubmed/27224915 http://dx.doi.org/10.18632/oncotarget.9507 |
Ejemplares similares
-
Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D
por: Gascoyne, Duncan M., et al.
Publicado: (2016) -
FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas
por: Brown, P J, et al.
Publicado: (2016) -
The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21(WAF1/CIP1) in 143B Osteosarcoma Cell Growth Arrest
por: Gascoyne, Duncan M., et al.
Publicado: (2015) -
CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model
por: Felce, Suet Ling, et al.
Publicado: (2020) -
Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas
por: Patel, Suketu, et al.
Publicado: (2014)